A clinical trial of the HDAC inhibitor belinostat was conducted in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma, and the objective response rate was 14% in patients with CTCL [64]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.